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We obtained conclusive linkage of Alzheimer disease (AD) with a candidate region of 19.7 cM at 7q36 in an
extended multiplex family, family 1270, ascertained in a population-based study of early-onset AD in the northern
Netherlands. Single-nucleotide polymorphism and haplotype association analyses of a Dutch patient-control sample
further supported the linkage at 7q36. In addition, we identiﬁed a shared haplotype at 7q36 between family 1270
and three of six multiplex AD-affected families from the same geographical region, which is indicative of a founder
effect and deﬁnes a priority region of 9.3 cM. Mutation analysis of coding exons of 29 candidate genes identiﬁed
one linked synonymous mutation, g.38030GrC in exon 10, that affected codon 626 of the PAX transactivation
domain interacting protein gene (PAXIP1). It remains to be determined whether PAXIP1 has a functional role in
the expression of AD in family 1270 or whether another mutation at this locus explains the observed linkage and
sharing. Together, our linkage data from the informative family 1270 and the association data in the population-
based early-onset AD patient-control sample strongly support the identiﬁcation of a novel AD locus at 7q36 and
re-emphasize the genetic heterogeneity of AD.
Alzheimer disease (AD [MIM 104300]) is a common
neurodegenerative disorder of the CNS that is charac-
terized by slowly progressing impairment of memory and
intellectual functioning that leads to dementia and, ulti-
mately, death. Clinical symptoms of AD most frequently
arise after age 65 years (late-onset AD); however, in !1%
of the patients, AD develops before age 65 years (early-
onset AD) (Ott et al. 1998). A deﬁnite diagnosis of AD
can be established only when pathological examination
of autopsied brain shows parenchymal senile plaques
composed largely of amyloid b and of intraneuronal neu-
roﬁbrillary tangles of hyperphosphorylated tau. Thus far,
positional cloning in multigeneration families with AD
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has identiﬁed three genes, coding for the amyloid pre-
cursor protein (APP [MIM 104760]) (21q21) (Goate et
al. 1991), presenilin 1 (PSEN1 [MIM 104311]) (14q23)
(Sherrington et al. 1995), and presenilin 2 (PSEN2 [MIM
600759]) (1q42.3) (Levy-Lahad et al. 1995; Rogaev et al.
1995). Currently, 172 differentmutations inAPP,PSEN1,
and PSEN2 have been documented in 363 families (Cruts
and Van Broeckhoven 1998; Alzheimer Disease & Fron-
totemporal Dementia Mutation Database). In addition,
the 4 allele of the apolipoprotein E gene (APOE [MIM
107741]) (19q13) was identiﬁed as a risk factor for both
early- and late-onset AD (Saunders et al. 1993; Stritt-
matter et al. 1993; van Duijn et al. 1994a). For ∼7%–
20% of patients, AD is attributable to APOE 4 (Slooter
et al. 1998; Warwick et al. 2000). Since the genetic cause
remains unknown in a signiﬁcant percentage of patients
with familial AD, including large families withwell-docu-
mented autosomal dominant AD (Pericak-Vance et al.
2000; Ashley-Koch et al. 2005; Jimenez-Escrig et al.
2005), it is clear that additional AD genes remain to be
identiﬁed.
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Figure 1 Pedigree of family 1270. A blackened symbol represents a patient, and an unblackened symbol represents an unaffected individual
or an at-risk individual with unknown phenotype. The Roman numbers to the left of the pedigree denote generations; Arabic numbers above
the symbols denote individuals. All numbering is in accordance with that of van Duijn et al. (1994b). The Arabic numbers below the symbols
denote age at onset for patients and either age at last examination or age at death for unaffected individuals and at-risk individuals with
unknown phenotype. An asterisk (*) indicates an individual who was included in the linkage analysis. The arrow identiﬁes the proband with
early-onset AD (age 47 years).
Table 1
Clinical Characteristics of Patients of Family 1270
PATIENT SEX
AGE (IN YEARS) AT
APOE
GENOTYPEa DIAGNOSISDisease Onset Death
II-1 F 68 72 … Dementiab
II-3 M 71 77 … MCIb
II-6 M 63 74 … Dementiab
II-7 F 65 70 … Dementiab
III-12 M 77 182 33 Probable AD
III-19c M 75 80 33 MCIb
III-21c F 72 … 44 Possible AD
III-36 M 65 70 … Possible AD
III-38 M 64 72 34 Probable AD
III-41c M 68 72 33 Probable AD
III-43c F 65 71 … Dementiab
III-45 F 47 60 44 Probable AD
III-48 M 69 175 34 Probable AD
a APOE genotypes of available patients in generation III (ﬁg. 1)
were determined elsewhere (van Duijn et al. 1994a).
b Diagnosis obtained through family informant.
c Newly diagnosed patients.
The present study was designed to identify additional
loci for AD by positional cloning in multigenerational
families. The source for our project was a sample of 110
patients with early-onset AD from a population-based
epidemiology study aiming to ascertain all patients with
early-onset AD in Rotterdam and the four northern prov-
inces of The Netherlands (Hofman et al. 1989). From
this sample, we had previously ascertained 10 multige-
nerational families for linkage studies (van Duijn et al.
1994b). In two families, a mutation in PSEN1 cosegre-
gated with the disease, whereas mutations in APP and
PSEN2 were absent (van Duijn et al. 1991; Cruts et al.
1998). Two other families, 1083 and 1270, were selected
for further linkage studies, since simulation linkage data
showed that each single family was sufﬁciently informa-
tive to generate signiﬁcant LOD scores independently.
In family 1083, genomewide linkage analysis identiﬁed
signiﬁcant linkage at 17q21 (multipoint LOD score 5.41
at D17S951; ) (Rademakers et al. 2002). Here,vp 0.0
we report on the clinical follow-up and the genetic analy-
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Figure 2 Brain CT scan of patient III-21 at age 82 years. The
legend is available in its entirety in the online edition of The American
Journal of Human Genetics.
Figure 3 Genomewide linkage data of the 10-cM density scan
of family 1270. The legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
ses of the three-generation family 1270. This family was
ascertained through its 47-year-old proband with early-
onset AD; a total of nine patients and seven at-risk in-
dividuals had cooperated, and blood samples had been
collected for genetic linkage studies (van Duijn et al.
1994b). A clinical follow-up of family 1270 was per-
formed by neurological examination of incident patients,
interviews of ﬁrst-degree relatives, and review ofmedical
records. Diagnoses of possible or probable ADweremade
according to National Institute of Neurological andCom-
municative Diseases and Stroke–Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) cri-
teria (McKhann et al. 1984), and that of mild cogni-
tive impairment (MCI) according to Honig and Mayeux
(2001). For ﬁve patients who were deceased or could
not be examined, diagnosis was complemented by infor-
mation obtained through a family informant. Since the
ﬁrst report (van Duijn et al. 1994b), four family mem-
bers (III-19, III-21, III-41, and III-43) became symptom-
atic. The updated pedigree of family 1270 is shown in
ﬁgure 1; clinical data is summarized in table 1. The over-
all clinical picture of family 1270 was compatible with
AD, with a mean ( SD) age at onset of 66.8 7.4
years ( ; age range 47–77 years) and a mean du-Np 13
ration of disease of years ( ; range of6.7 2.7 Np 10
duration 4–13 years). In proband III-45 and most other
patients, the disease initially presented with memory im-
pairment, except for patient III-38, in whom a change
of character was the initial complaint, later followed by
memory loss. In all patients, the disease progressed into
other areas of cognition, such as praxis and speech. Neu-
roimaging was available for two patients, III-48 at age
74 years and III-21 at age 82 years (table 1), which
showed cortical atrophy in both patients. For the only
living patient, III-21, who received the diagnosis of pos-
sible AD, a recent CT scan (at age 82 years) showed that
cortical and subcortical atrophy was most notable in the
temporal and frontal regions (ﬁg. 2). No brain pathology
of deceased patients was available for family 1270. Since
previous studies have already described mutations in the
genes encoding the microtubule-associated protein tau
(MAPT [MIM 157140]) and the prion protein (PRNP
[MIM 176640]) in patients who received a clinical di-
agnosis of AD but a pathological diagnosis, at autopsy,
of frontotemporal dementia (MIM 600274) or Creutz-
feld-Jacob disease (MIM 123400) (Dermaut et al. 2000;
Rademakers et al. 2003), the identiﬁcation of the pa-
thology underlying the dementia in family 1270 will be
important for the deﬁnite classiﬁcation of the inherited
dementia in this family.
We performed a genomewide linkage analysis of family
1270, using 400 microsatellite markers of the ABI Prism
Linkage Mapping Set MD-10 Version 2 (Applied Biosys-
tems). Microsatellite markers were analyzed on an auto-
mated ABI 377 or ABI 3700 DNA-Analyzer (Applied
Biosystems). For allele identiﬁcation and scoring,GENE-
SCAN and GENOTYPER were used (Applied Biosys-
tems). We calculated linkage analysis with the assump-
tion of an autosomal dominant mode of inheritance and
a disease frequency of 0.1%. A cumulative risk curve
was calculated with use of mean age at onset in the
family and the assumption of a maximal disease pene-
trance of 85% at age 85 years, and ﬁve disease pene-
trance classes were deﬁned. Age-dependent phenocopy
rates were deﬁned on the basis of the literature (Ott et
al. 1995). All patients with AD and MCI were consid-
ered affected in the linkage analysis. The phenotypes of
individuals I-1 and I-2 were considered unknown. Two-
point and multipoint LOD scores were calculated using
MLINK and LINKMAP options of the computer pack-
age Linkage, version 5.1 (Lathrop et al. 1985), with use
of equal recombination rates for males and females. Us-
ing this linkage model, we obtained a genomewide
conclusive LOD score of 3.39, at , only withvp 0.00
markerD7S798 at 7q36 (table 2). The ﬂanking markers,
D7S636 and D7S2465, also showed positive LOD scores
of 2.69 and 1.70, respectively, at . A summaryvp 0.00
of all two-point LOD scores obtained in the genomewide
scan is provided in ﬁgure 3. To ﬁne map the candidate
region at 7q36, we analyzed an additional 13 micro-
satellite markers in a 26.9-cM interval ﬂanked by mark-
ers D7S661 and D7S2423, including 9 markers from
the Marshﬁeld (Center for Medical Genetics) sex-aver-
aged linkage map, 1 marker from the genetic map of
the Cooperative Human Linkage Center, and 3 novel
markers—pRR8, pRR10, and pRR15—identiﬁed using
the Tandem Repeat Finder program (table 2) (Benson
1999). The highest two-point LOD score, 3.41, was ob-
tained with D7S1807 in the absence of recombinants.
The maximum multipoint LOD score was 3.47 (data
not shown). By use of the genotype data of 17 markers,
haplotypes at 7q36 were reconstructed, with considera-
646 Am. J. Hum. Genet. 77:643–652, 2005
Table 2
Two-Point LOD Scores for 7q36 Markers in Family 1270
MARKERa
DISTANCEb
(cM)
LOD AT vp
.00 .01 .05 .10 .20 .30 .40
D7S661 .0 1.31 .93 .40 .15 .01 .02 .01
D7S668 4.4 .68 .34 .97 1.15 1.09 .78 .32
D7S505 6.1 .30 1.28 1.76 1.80 1.52 1.03 .43
D7S636 7.2 2.69 2.65 2.46 2.22 1.68 1.08 .43
pRR8c … 1.08 .09 .53 .73 .70 .45 .15
D7S642 7.2 1.26 1.29 1.32 1.26 1.01 .64 .24
D7S2439 8.6 2.88 2.83 2.62 2.34 1.74 1.09 .42
D7S483 10.1 3.32 3.27 3.04 2.74 2.08 1.34 .55
D7S798 13.9 3.39 3.33 3.11 2.81 2.14 1.38 .57
D7S1807d … 3.41 3.36 3.14 2.84 2.16 1.40 .58
D7S2546 17.9 2.51 2.47 2.26 1.99 1.41 .82 .28
D7S1823 18.6 2.72 2.69 2.52 2.29 1.74 1.12 .44
pRR10c … 1.95 1.90 1.73 1.52 1.07 .61 .20
D7S2465 25.1 1.70 1.67 1.56 1.41 1.06 .65 .23
pRR15c … 3.11 3.06 2.85 2.57 1.95 1.26 .52
D7S559 26.9 1.41 1.61 1.84 1.82 1.49 .98 .38
D7S2423 26.9 1.04 .82 .45 .28 .14 .06 .02
a Markers from the 10-cM genomewide scan are in bold italics.
b Genetic distances were deduced from the Marshﬁeld (Center for Medical Genetics)
sex-averaged linkage map.
c pRR8 is located in AC010973.6 starting at nt 93259, pRR10 in AC078834.5 at
nt 132119, and pRR15 in AC005534.2 at nt 148849. The number of different alleles
observed within family 1270 was three for pRR10, four for pRR8, and ﬁve for pRR15.
d Selected from the genetic map of the Cooperative Human Linkage Center.
tion of minimal intermarker recombination (ﬁg. 4). In
the linkage pedigree, a disease haplotype was present in
all patients, and obligate recombinants deﬁned a candi-
date region of 19.7 cM between pRR8 (individuals III-
12, III-19, and III-21) and D7S559 (individual III-38). To
estimate the contribution of the 7q36 locus in the Dutch
population, we genotyped eight microsatellite markers in
102 patients with AD from the population-based early-
onset AD sample, recruited from the same geographical
region as family 1270 (Hofman et al. 1989), and 187
age- and sex-matched control individuals, drawn from
a large Dutch population-based cohort study of chronic
diseases of the elderly (Hofman et al. 1991). Markers
D7S1807 andD7S483were excluded from further analy-
sis: D7S1807 because the linked allele was not observed
in any of the patients with early-onset AD, which in-
dicated that the linked allele is extremely rare (frequency
!1%) in AD-affected individuals, and D7S483 because
120 different alleles were observed, which is indicative
of genetic instability. When we calculated single-marker
associations with the remaining six markers in the Dutch
early-onset AD patient-control sample with use of Gene-
pop, we identiﬁed signiﬁcant allelic association with
D7S798 ( ) (table 3). This association could bePp .03
explained in part by an increase of the rare 80-bp allele,
also linked to AD in family 1270, from 1.9% in control
individuals to 4.9% in patients with early-onset AD
( ). Examination of individual genotype dataP p .04specific
of D7S798 revealed that 4 of the 10 patients with early-
onset AD who carried the 80-bp allele at D7S798 were
probands of families with autosomal dominant AD. We
estimated that, in the Dutch patient-control sample, the
risk of AD for subjects carrying the 80-bp allele was 2.7
times higher (OR 2.69; 95% CI 1.01–7.17) than for
noncarriers.
In the populationwith early-onset AD, six patientswere
probands of families with multiplex AD, which is con-
sistent with autosomal dominant inheritance (van Duijn
et al. 1994b); they were not included in the genomewide
scan, because none had individually sufﬁcient genetic in-
formation to detect conclusive linkage. In all six pro-
bands, the onset of AD was at age65 years (van Duijn
et al. 1994b). In three families (1034, 1104, and 1125),
the mean age at onset of the relatives was !65 years,
whereas the three other families (1027, 1094, and 1242)
showed a mean onset of dementia at age 165 years (table
4). The genotypes of the families withmultiplex ADwere
compared for allele sharing with those of family 1270
(table 4). In three families (1034, 1125, and 1242), allele
sharing was observed of the rare 80-bp allele atD7S798,
as well as the linked alleles at two neighboring markers
(D7S2439 and D7S2546). The frequency of the shared
haplotype that was calculated on the basis of the fre-
quencies of the linked alleles in Dutch control individuals
was 0.6%. Also, all six markers were genotyped in ad-
ditional patients as well as relatives of families 1034 (2
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Figure 4 Disguised linkage pedigree of family 1270 (ﬁg. 1). Haplotypes are based on 17 informative markers at 7q36. Haplotypes for
individuals from the ﬁrst and second generations were inferred from genotype data of siblings and offspring. The risk haplotype was arbitrarily
set for individual I-2. For conﬁdentiality reasons, haplotypes are shown only for patients; the number of at-risk individuals included in the
genotyping are indicated by numbers within diamonds.
patients), 1125 (2 patients), and 1242 (1 patient), and
segregation analysis of the shared alleles was performed
to deﬁne haplotypes (ﬁg. 5). In family 1034, all three
patients with AD (III-4, III-6, and III-8) inherited the
201-80-232 haplotype. Segregation analysis of family
1242 revealed that both patients (III-14 and III-20) car-
ried the 80-232 haplotype. The lack of sufﬁcient segre-
gation information precluded haplotype determination
in family 1125. However, allele sharing in the two ad-
ditional patients from that family identiﬁed the linked
201-80-232 alleles in one patient (III-1), whereas the
other patient (III-2) shared the 201-80 alleles. Together,
these studies delineated a priority region—betweenmark-
ers D7S2439 and D7S2546, with a maximum genetic
distance of 9.3 cM—that is shared by families 1270, 1034,
1242, and 1125. Two-marker sliding-window haplotype
analysis in the early-onset AD patient-control sample,
with use of the expectation maximization algorithmpro-
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Table 3
Allelic Frequencies and Association Analysis of Dutch
Patient-Control Sample of Early-Onset AD, at 7q36
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 4
Allele-Sharing Analysis of Microsatellite Markers at 7q36
MARKER
LINKED ALLELE
IN FAMILY 1270
(bp)
FREQUENCY OF
LINKED ALLELE
IN CONTROL
INDIVIDUALS
(%)
GENOTYPE (ALLELES IN BP) OF AUTOSOMAL DOMINANT FAMILY
1027a 1034b 1094c 1104d 1125e 1242f
D7S642 189 45.4 189–191 189–191 189–191 189–197 195–195 191–191
D7S2439 201 29.4 201–201 201–201 195–195 199–209 199–201 199–201
D7S798 80 1.9 82–84 80–88 84–84 90–92 80–82 80–92
D7S2546 232 18.6 238–238 232–236 195–195 199–209 232–238 232–232
D7S1823 217 12.3 217–225 221–225 84–84 90–92 221–229 209–237
D7S2465 175 23.5 180–184 173–176 169–173 175–183 173–177 173–177
NOTE.—The linked alleles of family 1270 are in bold italics. Ages at onset are taken from the publication by van Duijn
et al. (1994b).
a Number of patients with ; mean ( SD) age at years; age range 57–92 years.dementiap 3 onsetp 72.3 17.9
b Number of patients with ; mean age at ; age range 56–70 years.dementiap 4 onsetp 61.3 6.1
c Number of patients with ; mean age at ; age range 61–80 years.dementiap 6 onsetp 70.5 8.0
d Number of patients with ; mean age at ; age range 40–67 years.dementiap 9 onsetp 51.9 9.7
e Number of patients with ; mean age at ; age range 49–70 years.dementiap 5 onsetp 58 8.6
f In family 1242, we analyzed allele sharing in patient III-14, since DNA of the proband (III-20) was no longer available
(van Duijn et al. 1994b). Number of patients with ; mean age at ; age range 63–80 years.dementiap 4 onsetp 72 7.7
vided by the Arlequin package, further revealed that the
201-80 haplotype of D7S2439-D7S798 signiﬁcantly in-
creased from 0.5% in control individuals to 3.4% in pa-
tients with AD ( ; OR 6.52; 95% CI 1.34–P p .007specific
31.71). The haplotype-sharing data of the four Dutch
families with early-onset AD is suggestive of a common
founder for AD that is linked to the 7q36 locus in the
Dutch population. We documented elsewhere the foun-
der effects within the Dutch population with early-onset
AD, since all patients carrying the PSEN1 Ala79Val mu-
tation or the Glu318Gly polymorphism shared an ex-
tended haplotype (Cruts et al. 1998; Dermaut et al.
1999). Comparison of the onset ages in the four families
with multiplex AD also identiﬁed relatively similarmean
ages at onset (58.0, 61.3, 66.8, and 72.0 years), with
wide intrafamilial ranges (14–30 years) that showed pa-
tients with both early- and late-onset AD in each family,
which further supported a common phenotype in these
families. Previous studies of families with AD have
shown that the age at onset can be inﬂuenced by the
APOE genotype, with APOE 4 carriers having an age
at onset earlier than that of noncarriers of APOE 4
(Corder et al. 1993; van Duijn et al. 1994a). However,
since ages at onset were 47 and 72 years for two patients
homozygous for APOE 4 in family 1270 (table 1), it
is unlikely that the broad onset range in the patients
with AD in this family is explained by APOE genotypes.
Also, in the three families who share a disease haplotype
at 7q36, all patients with available DNA were homo-
zygous for APOE 4, whereas ages at onset varied from
51 to 80 years (van Duijn et al. 1994a).
We assembled the genomic sequence of the candidate
region in family 1270, between pRR8 andD7S559, using
publicly available ﬁnished and unﬁnished sequences of
large-insert clones. This resulted in two contiguous se-
quences, of 4.03 Mb and 1.33 Mb, separated by a se-
quence gap of ∼80 kb located between D7S1823 and
pRR10 (table 2) (Hillier et al. 2003). In family 1270, the
candidate region segregating the disease gene at 7q36 was
therefore estimated at 5.44 Mb. The priority region be-
tween D7S2439 and D7S2546 that was shared by the
four dominant families with AD corresponded to an es-
timated physical size of 2.94 Mb. In the course of this
study, the complete sequence assembly of 7q36 became
available through public genome annotation databases
(National Center for Biotechnology Information [NCBI]
MapViewer; University of California–SantaCruz [UCSC]
Genome Bioinformatics). Although two gaps remained in
the public genome assembly (NCBI build 34), no major
inconsistencies in sequence order were observed with our
independently assembled sequence contigs. Within the
5.44-Mb candidate region, we determined the location
and genomic organizations of 29 genes by annotating the
candidate sequence contigs on the basis of homologywith
genes and proteins of human and other species, ESTs, and
predicted genes and exons (table 5). These included 20
validated, reviewed, and provisional RefSeq genes located
in the 150.2–155.8 Mb region of NCBI build 34 of the
UCSC Human Genome Browser (UCSC Genome Bioin-
formatics). We performed mutation analysis of 28 genes
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Table 5
Overview of Analyzed Candidate Genes at 7q36
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 5 Linkage pedigrees of Dutch families with early-onset AD who share haplotypes at 7q36. Blackened symbols represent patients
with AD; unblackened symbols represent unaffected individuals or at-risk individuals with unknown phenotype. Roman numbers to the left of
the pedigree denote generations; Arabic numbers above the symbols denote individuals. All numbers are in accordance with those used in the
complete pedigrees published by van Duijn et al. (1994b). For patients, the age (in years) at onset is shown below the symbol. An asterisk (*)
indicates that DNA was available for genetic analysis. The arrow identiﬁes the proband. To protect privacy of at-risk individuals, the shared
haplotypes are shown only for patients. Haplotypes for individual III-20 in family 1242 and individual III-4 in family 1034 were reconstructed
from genotype data obtained from their siblings and offspring. For family 1125, only genotype data are given, since segregation data were not
informative for deduction of haplotypes.
from the candidate region by direct genomic DNA
(gDNA) sequencing of PCR amplicons of all coding exons
in three patients (III-12, III-41, and III-48) and one control
individual of family 1270. On the basis of gDNA and
cDNA sequence alignment, intronic PCRprimers ﬂanking
coding exons were developed using SNPbox (Weckx et
al. 2005). For the gene encoding myeloid and lymphoid
leukemia 3 (MLL3), mutation analysis was performed by
cDNA sequencing in two patients (III-38 and III-41) and
one control individual. DNA sequences were determined
by cycle sequencing with the BigDye Cycle Sequencing kit
(Applied Biosystems) and were analyzed on an ABI 3700
and ABI 3730 DNA analyzer (Applied Biosystems). In
total, we identiﬁed 167 sequence variations: 24 missense
and 21 silent mutations in 18 genes, and 122 intronic
variations (data not shown). Seven single-nucleotide
changes in ﬁve different genes segregated in family 1270
on the disease haplotype (table 6). However, analysis of
gDNA of 40 Dutch control individuals indicated that six
of the seven sequence variants were common polymor-
phisms, with frequencies of the linked allele varying from
10.7% to 54.0% (table 6). Only g.38030GrC in exon
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Table 6
Sequence Variations Segregating on the Disease Haplotype
in Family 1270
Genea, GenBank
Clone Number,
and Variant
Predicted
Effect on
Amino
Acid
Linked
Allele
Frequencyb
in Control
Individuals
(%)
Restriction
Enzymec
ABCF2:
AC021097.5:
g.16531CrT LeurLeu T 26.2 …
g.19567GrC … C 33.3 HinfI
GALNTL5:
AC074257.5:
g.176022ArG GlurGly G 19.8 …
DPP6:
AC006019.2:
g.57910CrT GlyrGly T 18.1 …
PAXIP1:
AC093726.3:
g.38030GrC AlarAla C .0 Bsh1236I
EN2:
AC008060.5:
g.89332GrA ProrPro A 10.7 SmaI
g.89582TrC PherLeu C 54.0 AluI
a ABCF2: ATP-binding cassette subfamily F, member 2;GALNT11:
N-acetylgalactosaminyltransferase 11; DPP6: dipeptidylpeptidase 6;
PAXIP1: PAX transcription activation domain interacting protein;
EN2: engrailed 2.
b Allele frequencies for all variations were estimated in 80 control
chromosomes. For g.38030GrC in PAXIP1, an additional 560 control
chromosomes were tested.
c Control individuals were genotyped by a PCR-RFLP assay and
electrophoresis of the PCR fragments on a 2% agarose gel or, if the
mutation did not affect a restriction enzyme site, by direct sequencing.
Figure 6 Expression analysis of PAXIP1. The legend is available
in its entirety in the online edition of The American Journal of Human
Genetics.
10 of PAXIP1, which predicted a silent Ala626mutation,
was absent in the 40 control individuals and in an ad-
ditional 280 Dutch control individuals, which resulted in
a C-allele frequency of !0.16% (!1/640 chromosomes).
When we examined the expression proﬁle of PAXIP1 on
a multiple-human-tissue northern blot, we identiﬁed a
4.5-kb transcript of PAXIP1 in all tissues analyzed, except
in liver, in which an alternative PAXIP1 transcript of 1.5
kb was expressed (ﬁg. 6). Brain expression analysis of
PAXIP1 by RT-PCR identiﬁed PAXIP1 transcripts in
seven different brain regions, including frontal and tem-
poral regions affected in AD-affected brains (ﬁg. 6). Al-
though g.38030GrC is located 10 bp upstream of the
intron 10 splice-donor site, a preliminary RT-PCR analy-
sis of lymphoblast cDNA of two patients (III-38 and III-
41) and one control individual of family 1270 did not
suggest aberrant PAXIP1 splicing. PAXIP1 g.38030GrC
was also not observed in the sample of patients with early-
onset AD, including the three probands of the families
with autosomal dominant disease who share the priority
region between markers D7S2439 and D7S2546. Since
PAXIP1 is outside the shared region at 0.44 Mb down-
stream of the associated D7S2546, the absence of
g.38030GrC in the three probands does not contradict
a founder effect. Sequencing of PCR amplicons of all cod-
ing exons in gDNA of the probands of the six autosomal
dominant families further excluded other coding genetic
variants in PAXIP1, except for the known g.56231ArG
variant (rs3501); this predicts a Met979Val mutation in
exon 18, with a frequency of 26.9% for the G-allele,
which was present in two heterozygous individuals and
one homozygous autosomal dominant proband. Also, ex-
pansion of a polyglutamine repeat in PAXIP1 exon 7
was excluded in six patients of family 1270, by Southern
blot analysis of PCR-ampliﬁed exon 7 genomic fragments.
Since PAXIP1 g.38030GrC was absent in the three fam-
ilies with multiplex AD who potentially share a common
founder with family 1270 and since we limited our mu-
tation analysis to coding regions, we cannot exclude the
possibility that a mutation in 1 of the other 28 positional
candidate genes might be the underlying genetic defect in
family 1270. Also, a mutation not detected by genomic
sequencing of exons—for example, whole-exon dele-
tion—remains plausible. Further, our current annotation
efforts might have missed coding sequences. The assem-
bled sequence of the candidate region still contains a gap
of ∼80 kb between the genes INSIG1 and EN2 in which
additional genes might be present, although the syntenic
region in mouse does not contain genes.
Together, our linkage data of the informative family
1270, the association data of the population-based pa-
tient-control sample of early-onset AD, and the haplo-
type-sharing data of probands of three additional fami-
lies with multiplex AD strongly support the locus at 7q36
as a novel locus for AD. Mutation analysis of all 29
known genes in the candidate region identiﬁed only an
exonic silent mutation in PAXIP1, segregating in family
1270, which was absent from 640 control chromosomes
(mutant allele frequency !0.16%). However, whether
PAXIP1 has a functional role in expression of AD in
family 1270 remains unclear. The novel AD locus at 7q36
provides further evidence that AD is highly genetically
heterogeneous, with genes at different loci contributing
to the expression of the phenotype. In addition, it can
be expected that the identiﬁcation of the underlying gene
defect at 7q36 might largely contribute to our current
understanding of the genetic etiology and pathogenesis
of AD.
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Web Resources
Accession numbers and URLs for data presented herein are
as follows:
Arlequin, http://lgb.unige.ch/arlequin/ (for estimation of haplo-
type frequencies)
Alzheimer Disease & Frontotemporal Dementia Mutation Da-
tabase, http://www.molgen.ua.ac.be/ADMutations/
Center for Medical Genetics, http://research.marshﬁeldclinic
.org/genetics/ (for the Marshﬁeld Medical Research Foun-
dation and marker position and extra markers in region of
interest)
Cooperative Human Linkage Center, http://gai.nci.nih.gov/
CHLC/ (for extra marker in region of interest)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for PAXIP1
[accession numbers AC093726.3 and NM_007349.6],
ABCF2 [accession number AC021097.5], GALNT11 [ac-
cession number AC074257.5], DPP6 [accession number
AC006019.2], and EN2 [accession number AC008060.5])
Genepop, http://wbiomed.curtin.edu.au/genepop/ (for single
SNP association analysis)
NCBI Map Viewer, http://www.ncbi.nlm.nih.gov/mapview/ (for
gene position as well as links to sequence and protein func-
tion information)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for AD, APP, PSEN1, PSEN2,
APOE, MAPT, PRNP, frontotemporal dementia, and Creutz-
feld-Jacob disease)
SNPbox, http://www.snpbox.org/
UCSC Genome Bioinformatics, http://genome.ucsc.edu/ (for
gene position and sequence information)
VIB8 Genetic Service Facility, http://www.vibgeneticservice
facility.be/
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